CannabisNewsBreaks Archive - Page 2 of 396

FridayNov 18, 2022 3:04 pm

CannabisNewsBreaks – REZYFi Inc. Leading Industry with Diversified Approach to Real Estate Lending Sector

REZYFi, a growth mortgage origination and specialized financing company servicing the needs of both traditional and non-traditional consumers and businesses, is uniquely positioned as the first cannabis mortgage banker in the United States. “REZYFi operates through two wholly owned subsidiaries – REZYFi Lending and ResMac, Inc. REZYFi Lending leverages a wide network to offer options such as 15- to 30-year fixed-rate, FHA, VA, and jumbo loans and reverse and adjustable-rate mortgages. The company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the company’s launch of a high-margin…

FridayNov 18, 2022 12:34 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Treatment Poised to Provide Reprieve to Millions of Patients

Lexaria Bioscience Corp. (NASDAQ: LEXX) is developing a potential hypertension treatment with little to no side effects. “The treatment is created by processing cannabidiol (‘CBD’) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (‘APIs’). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood by as much as 317% but also reduces blood pressure and arterial stiffness,” a recent article reads. “Lexaria hopes to prove, through registered clinical trials, that its DehydraTECH-CBD formulation has an acceptable safety and tolerability…

FridayNov 18, 2022 10:43 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has entered into a securities purchase agreement with two healthcare-focused institutional investors. The agreement outlines plans for the issuance and sale of 1,818,185 of INM common shares; the shares will be issued at a purchase price of $3.30 per share or prefunded warrant. In addition, the agreement notes that INM will issue unregistered preferred investment options to the same investors; those options include purchasing up to 3,272,733 additional common shares. According to the announcement, the company anticipates the private placement, which…

ThursdayNov 17, 2022 2:00 pm

CannabisNewsBreaks — AROYA Extends Utility of Cannabis Production Platform

AROYA, a METER Group Company, announced that it is incorporating new integrations that extend the utility of its Cannabis Production Platform. The strategic move will enable integrations with third-party systems, further strengthening AROYA’s position as the cannabis industry’s most intuitive platform. The AROYA platform gives growers with control, flexibility, visibility and data-driven insights to help them manage every stage of cultivation. According to the announcement, AROYA’s Automated Irrigation Control integrates seamlessly with OpenSprinkler controllers, enabling users to set, manage and monitor drip irrigation schedules through an app and eliminating the need to log into additional programs or keep data logged…

ThursdayNov 17, 2022 11:30 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Accounting VP, Controller

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has named Sarah Li as vice president of accounting and InMed controller; the change will be effective Nov. 20, 2022. Li is replacing Brenda Edwards, who has been serving as interim chief financial officer for the company. Edwards joined InMed in the interim contract role in March after the company’s CFO retired. “We are pleased to announce this promotion of Ms. Li to her new position as VP of Accounting and Controller,” said InMed president and CEO Eric A. Adams in…

WednesdayNov 16, 2022 4:27 pm

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) GrowPods Can Eliminate Food Deserts Virtually Anywhere

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of self-contained, automated, indoor “micro-farms” called GrowPods, is working to provide viable ways for communities to grow food where it is needed most. The ability to eradicate “food deserts” is a powerful benefit of ACTX’s GrowPods; food deserts are defined by the U.S. Department of Agriculture as an area with no ready access to a store with fresh and nutritious food options within one mile for urban areas and 10 miles or more from the nearest market for rural America. GrowPods are portable, controlled-environment container farms that grow ultra-clean, healthy food…

WednesdayNov 16, 2022 2:42 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Marks Key Step in Progress Toward Commercializing Medicinal Cannabis

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced the completion of its new laboratory located in Bogota, Colombia. Specializing in the manufacturing of compound formulations utilizing cannabis derivatives and traditional master formulas, Flora Lab 4 will become part of Flora’s group of laboratories. These include existing labs that produce cosmetics, phytotherapeutic products, dietary supplements, and cannabis extraction and transformation. “The completion of Flora Lab 4 is an important step in Flora Growth’s progress toward commercializing medicinal cannabis. This lab is built to produce prescription-grade medications and manufacture cannabis-based formulations,” said…

WednesdayNov 16, 2022 2:00 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation to the treatment of neurodegenerative diseases; the new program will focus on two lead analogs to conduct studies using in vivo models to select the most appropriate candidate for clinical studies. The company anticipates that early preclinical…

MondayNov 14, 2022 12:19 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Partners with 357 Company to Launch Cannabis Division

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is working with the 357 Company to launch 357’s Canna Logistics division. The new division is an expansion beyond 357’s Hemp Logistics segment, which ships federally legal hemp within the United States. According to the announcement, the new division will focus on logistics management and shipping of cannabis and hemp between countries where cannabis has been legalized. 357 is working to expand into international shipping of cannabis, hemp and industrial hemp; the cannabis export/import industry is new and poses significant potential for shipments of…

MondayNov 14, 2022 12:04 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has reported its financial results for the first quarter of fiscal year 2023, ended Sept. 30, 2022. Highlights of the report included updates on the company’s pharmaceutical development programs, including INM-755 for the treatment of epidermolysis bullosa (“EB”) and INM-088 for the treatment of glaucoma. According to the report, enrollment and patient treatment in the company’s phase 2 clinical trial for INM-755 should be complete by the end of the year while the company continues to conduct key preclinical work including toxicology and GLP studies in…

News and publishing service for cannabis related companies

Contact us: 303.498.7722

CannabisNewsBreaks